Mannkind reported $26.04M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Adma Biologics ADMA:US $ 15.89M 1.78M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Chemocentryx CCXI:US $ 28.18M 2.17M
Dynavax Technologies DVAX:US $ 35.74M 4.27M
Eli Lilly And LLY:US $ 1.63B 67.2M
Halozyme Therapeutics HALO:US $ 57.48M 43.64M
Immunogen IMGN:US $ 23.79M 7.14M
Insmed INSM:US $ 59.97M 3.23M
JAZZ PHA JAZZ:US 325.67M 16.86M
Karyopharm Therapeutics KPTI:US $ 37.34M 1.43M
Macrogenics MGNX:US $ 13.67M 2.58M
Mannkind MNKD:US $ 26.04M 5.35M
Merk MRK:US $ 2.42B 118M
Minerva Neurosciences NERV:US $ 2.83M 196.19K
Novavax NVAX:US $ 108.16M 12.17M
Novo Nordisk A Fs NVO:US 11.83B 678M
Peregrine Pharmaceuticals PPHM:US $ 6.38M 467K
Pfizer PFE:US $ 3.2B 506M
Xencor XNCR:US $ 11.09M 182K